Latest news with #investorlosses
Associated Press
6 days ago
- Business
- Associated Press
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biohaven
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Biohaven To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Biohaven between March 24, 2023 and May 14, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Biohaven Ltd. ('Biohaven' or the 'Company') (NYSE: BHVN) and reminds investors of the September 12, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) troriluzole's regulatory prospects as a treatment for SCA, and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (2) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (3) all the foregoing, once revealed, was likely to have a significant negative impact on Biohaven's business and financial condition; and (4) as a result, Defendants' public statements were materially false and misleading at all relevant times. On May 14, 2025, Biohaven issued a press release 'announc[ing] that the Division of Neurology 1 within FDA's Office of Neuroscience informed the Company that they are extending the PDUFA date for the troriluzole new drug application (NDA) for the treatment of spinocerebellar ataxia (SCA) by three months to provide time for a full review of Biohaven's recent submissions related to information requests from the FDA.' The press release further stated that "[t]he Division also informed Biohaven that it is currently planning to hold an advisory committee meeting to discuss the application, but no date has been scheduled.' On this news, Biohaven's stock price fell $3.84 per share, or 19.53%, to close at $15.82 per share on May 15, 2025. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Biohaven's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Biohaven class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. A photo accompanying this announcement is available at
Associated Press
14-07-2025
- Business
- Associated Press
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Petco
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Petco To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Petco between January 14, 2021 and June 5, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - July 14, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Petco Health and Wellness Company, Inc. ('Petco' or the 'Company') (NASDAQ: WOOF) and reminds investors of the August 29, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. [ This image cannot be displayed. Please visit the source: ] Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) Petco's pandemic-related tailwinds were unsustainable, as was its business model of selling primarily premium and/or high-grade pet food; (ii) accordingly, the strength of Petco's differentiated product strategy was overstated; (iii) Defendants downplayed the true scope and severity of the foregoing issues, the magnitude of changes needed to rectify those issues, and the likely negative impacts of their mitigation strategy on Petco's comparable sales metric; (iv) accordingly, Defendants overstated Petco's ability to deliver sustainable, profitable growth; and (v) as a result, Defendants' public statements were materially false and misleading at all relevant times. On June 5, 2025, Petco issued a press release reporting its financial results for the first quarter of 2025. Among other items, Petco reported net sales of $1.5 billion, representing a 2.3% year-over-year decline. On this news, Petco's stock price fell $0.85 per share, or 23.34%, to close at $2.78 per share on June 6, 2025. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Petco's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Petco class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. To view the source version of this press release, please visit
Bloomberg
07-07-2025
- Business
- Bloomberg
Indian Retail Traders Lose $12 Billion Trading Equity Options
Individuals in India lost over 1 trillion rupees ($12.2 billion) during the year ended March, trading equity derivatives in the world's top destination for such products, according to a study by the country's securities regulator. Nine out of 10 mom-and-pop investors suffered losses, the study published on Monday by the Securities and Exchange Board of India found. Retail investors had lost 748.12 billion rupees in the financial year ended March 2024, the study showed.
Associated Press
29-06-2025
- Business
- Associated Press
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Open Lending
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Open Lending To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Open Lending between February 24, 2022 and March 31, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - June 29, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Open Lending Corporation ('Open Lending' or the 'Company') (NASDAQ: LPRO) and reminds investors of the June 30, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. [ This image cannot be displayed. Please visit the source: ] Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants: (1) misrepresented the capabilities of the Company's risk-based pricing models; (2) issued materially misleading statements regarding the Company's profit share revenue; (3) failed to disclose the Company's 2021 and 2022 vintage loans had become worth significantly less than their corresponding outstanding loan balances; and (4) misrepresented the underperformance of the Company's 2023 and 2024 vintage loans. As a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. On March 17, 2025, Open Lending announced the postponement of its earnings release and conference call, both originally scheduled for the same day. The company also filed a Form 12b-25, requesting additional time to finalize its financial statements for its annual 10-K report. On this news, Open Lending's stock price fell $0.40, or 9.3%, to close at $3.91 per share on March 17, 2025, thereby injuring investors. Subsequently, on March 31, 2025, Open Lending reported a substantial year-over-year increase in its net loss for Q4 2024, largely attributable to the recognition of a valuation allowance on its deferred tax assets, which elevated its income tax expense for the period. Additionally, the company disclosed significant leadership changes. On this news, Open Lending's stock price fell $1.59, or 57.61%, to close at $1.17 per share on April 1, 2025, thereby injuring investors. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Open Lending's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Open Lending Corporation class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. To view the source version of this press release, please visit
Associated Press
14-06-2025
- Business
- Associated Press
Abacus Global Management, Inc. (ABL) Shares Tumble Following Second Morpheus Report
SAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- Investors in Abacus Global Management, Inc. (NASDAQ: ABL) experienced another substantial decline in share price today following the release of a second scathing report from Morpheus Research. Morpheus, a collective of financial analysts known for their focus on uncovering alleged fraud and corporate malfeasance, has now published two critical analyses of Abacus within a week, alleging the life settlements company has engaged in improper accounting. Hagens Berman is investigating Morpheus Research's allegations and urges Abacus investors who suffered substantial losses to submit your losses now . The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys. Visit: Contact the Firm Now: [email protected] 844-916-0895 The Abacus Global Management, Inc. (ABL) Investigation: Abacus represents itself as a 'leading' financial services company specializing in alternative asset management, data driven wealth solutions, technology innovations, and institutional services. Under relevant accounting rules, Abacus is required to report the value of its assets in conformity with generally accepted accounting principles, which the company has consistently assured investors that it has. Abacus' assurances may have come into question on June 4, 2025, when Morpheus Research published its initial report, alleging that Abacus was engaged in an 'accounting scheme' within its life settlements portfolio. The report claimed Abacus manufactured 'fake revenue' by aggressively using 'mark-to-model' accounting and systematically underestimating the life expectancies of insured individuals. Morpheus further highlighted Abacus's reliance on Lapetus Solutions for life expectancy estimates, suggesting these calculations were questionable and that former employees and industry experts had raised concerns about their accuracy, contributing to an overvaluation of the company's assets. The information revealed in the initial Morpheus report caused Abacus Global's shares to decline over 20% decline in a single trading day. On June 10, 2025, Abacus published its purported rebuttal of Morpheus' June 4, 2025 forensic report and primarily reported that it retained an independent actuarial firm (Lewis and Ellis) who 'has maintained a sterling reputation' to vet the company's balance sheet in an effort to debunk Morpheus' conclusions. But, on June 12, 2025, Morpheus issued a second follow up report, asserting that Abacus's rebuttal to the initial claims was inadequate and contradictory to its own SEC filings. The follow report significantly escalated its allegations by presenting what Morpheus claimed was new evidence of undisclosed related-party dealings involving Abacus insiders and raising concerns about 'Carlisle Round-Tripping Policies,' thereby intensifying the scrutiny on the company's financial practices. Morpheus also cast doubt on Abacus's assertion that third-party validator Lewis & Ellis corroborated its valuations, noting Lewis & Ellis' prior involvement with another fund that faced lawsuits over flawed valuations and highlighting that Lewis & Ellis had previously relied on inputs provided by the fund itself. These events caused the price of Abacus shares to decline sharply. 'We're investigating whether Abacus may have misled investors about its asset values and, more recently, about the independence of Lewis and Ellis who purportedly vetted the company's asset valuations,' said Reed Kathrein, the Hagens Berman partner leading the investigation. If you invested in Abacus Global Management and have substantial losses, or have knowledge that may assist the firm's investigation, submit your losses now » If you'd like more information and answers to frequently asked questions about the Abacus Global investigation, read more » Whistleblowers: Persons with non-public information regarding Abacus Global Management should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected] . About Hagens Berman Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at . Follow the firm for updates and news at @ClassActionLaw . Contact: Reed Kathrein, 844-916-0895
